See more : Vijaya Diagnostic Centre Limited (VIJAYA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Hansa Biopharma AB (publ) (0RC7.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hansa Biopharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Global Partner Acquisition Corp II (GPACW) Income Statement Analysis – Financial Results
- ICICI Prudential Life Insurance Company Limited (ICICIPRULI.BO) Income Statement Analysis – Financial Results
- Yjn Co.,Ltd. (3191.TWO) Income Statement Analysis – Financial Results
- Cameo Communications, Inc. (6142.TW) Income Statement Analysis – Financial Results
- Nitto Boseki Co., Ltd. (3110.T) Income Statement Analysis – Financial Results
Hansa Biopharma AB (publ) (0RC7.L)
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 134.09M | 154.53M | 33.88M | 6.10M | 3.36M | 3.36M | 3.44M | 2.58M | 5.43M | 4.72M | 1.73M | 2.62M | 1.28M | 4.45M | 2.98M | 103.68K |
| Cost of Revenue | 63.14M | 38.48M | 15.43M | 997.00K | 866.00K | 916.00K | 221.00K | 217.00K | 658.00K | 245.00K | 317.96K | -2.49M | 1.71M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 70.95M | 116.05M | 18.45M | 5.10M | 2.50M | 2.44M | 3.22M | 2.36M | 4.78M | 4.47M | 1.41M | 5.11M | -432.44K | 4.45M | 2.98M | 103.68K |
| Gross Profit Ratio | 52.91% | 75.10% | 54.47% | 83.65% | 74.26% | 72.72% | 93.58% | 91.59% | 87.89% | 94.80% | 81.59% | 194.96% | -33.73% | 100.00% | 100.00% | 100.00% |
| Research & Development | 411.33M | 346.24M | 230.76M | 227.19M | 192.95M | 154.56M | 137.06M | 82.85M | 44.26M | 21.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 450.49M | 337.86M | 327.27M | 202.99M | 167.31M | 90.39M | 43.72M | 29.70M | 28.24M | 17.42M | 11.26M | 14.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 450.49M | 337.86M | 327.27M | 202.99M | 167.31M | 90.39M | 43.72M | 29.70M | 28.24M | 17.42M | 11.26M | 14.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -2.38M | 8.06M | 0.00 | 0.00 | -166.00K | -725.00K | -1.44M | 944.00K | -1.53M | 11.76M | 7.79M | 7.77M | 27.46M | 24.44M | 18.72M | 16.01M |
| Operating Expenses | 859.45M | 692.17M | 558.03M | 430.18M | 360.09M | 244.22M | 179.34M | 113.50M | 70.98M | 29.18M | 19.05M | 21.91M | 27.46M | 24.44M | 18.72M | 16.01M |
| Cost & Expenses | 922.59M | 730.65M | 573.46M | 431.18M | 360.96M | 245.14M | 179.56M | 113.71M | 71.64M | 29.43M | 19.37M | 19.43M | 29.18M | 24.44M | 18.72M | 16.01M |
| Interest Income | 27.99M | 8.83M | 67.00K | 388.00K | 118.00K | 52.00K | 97.00K | 23.00K | 0.00 | 42.00K | 93.22K | 346.44K | 47.78K | 9.70K | 6.97K | 16.52M |
| Interest Expense | 105.52M | 43.67M | 694.00K | 257.00K | 466.00K | 706.00K | 695.00K | 103.00K | 65.00K | 123.00K | 15.76K | 4.74K | 155.41K | 160.18K | 78.57K | 16.52M |
| Depreciation & Amortization | 10.74M | 12.05M | 8.61M | 7.55M | 6.91M | 1.84M | 3.78M | 3.45M | 989.00K | 1.35M | 96.65K | 126.79K | -52.36M | 0.00 | 381.77K | 415.40K |
| EBITDA | -714.55M | -554.26M | -538.83M | -413.08M | -352.21M | -245.47M | -172.30M | -107.60M | -65.21M | -28.13M | -17.45M | -16.33M | -24.29M | -19.99M | -15.36M | -15.47M |
| EBITDA Ratio | -532.88% | -355.47% | -1,588.95% | -6,801.44% | -10,466.94% | -7,284.69% | -5,004.68% | -4,174.49% | -1,200.07% | -494.44% | -1,010.39% | -623.73% | -2,175.42% | -449.46% | -514.75% | -14,925.86% |
| Operating Income | -788.50M | -576.12M | -539.58M | -425.08M | -357.60M | -246.50M | -176.08M | -111.14M | -66.20M | -24.71M | -17.64M | -16.81M | 24.46M | -19.99M | -15.74M | -15.91M |
| Operating Income Ratio | -588.02% | -372.83% | -1,592.72% | -6,970.76% | -10,630.05% | -7,340.62% | -5,115.72% | -4,309.23% | -1,218.27% | -523.94% | -1,021.38% | -641.80% | 1,907.97% | -449.46% | -527.54% | -15,341.72% |
| Total Other Income/Expenses | -42.32M | -33.86M | -1.15M | 1.91M | -2.00M | -1.52M | -616.00K | -17.00K | -65.00K | -4.33M | 67.00K | 331.97K | -107.63K | -150.48K | -71.60K | 16.52M |
| Income Before Tax | -830.81M | -609.98M | -548.13M | -420.89M | -359.59M | -248.01M | -176.70M | -111.15M | -66.27M | -29.04M | -17.56M | -16.47M | -24.57M | -20.14M | -15.81M | 616.70K |
| Income Before Tax Ratio | -619.57% | -394.74% | -1,617.95% | -6,902.15% | -10,689.42% | -7,385.77% | -5,133.61% | -4,309.89% | -1,219.47% | -615.82% | -1,016.90% | -628.75% | -1,916.36% | -452.84% | -529.94% | 594.83% |
| Income Tax Expense | 908.00K | 1.16M | 152.00K | -40.00K | 417.00K | -40.00K | -39.00K | -23.00K | 0.00 | 42.00K | 93.22K | 346.44K | 65.00 | -1.30M | 0.00 | 3.17M |
| Net Income | -831.72M | -611.13M | -548.28M | -420.85M | -360.01M | -247.97M | -176.66M | -111.13M | -66.27M | -29.04M | -17.56M | -16.47M | -24.57M | -18.84M | -15.81M | -2.56M |
| Net Income Ratio | -620.25% | -395.49% | -1,618.40% | -6,901.49% | -10,701.81% | -7,384.57% | -5,132.48% | -4,309.00% | -1,219.47% | -615.82% | -1,016.90% | -628.75% | -1,916.37% | -423.62% | -529.94% | -2,467.50% |
| EPS | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 | -4.97 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
| EPS Diluted | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 | -4.96 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
| Weighted Avg Shares Out | 52.54M | 44.92M | 44.47M | 42.18M | 40.02M | 38.33M | 35.52M | 32.98M | 31.21M | 26.54M | 24.54M | 23.24M | 11.64M | 8.31M | 5.06M | 5.00M |
| Weighted Avg Shares Out (Dil) | 52.54M | 44.92M | 44.47M | 42.18M | 40.02M | 38.33M | 35.61M | 33.01M | 31.21M | 26.54M | 24.54M | 23.24M | 11.64M | 8.31M | 5.06M | 5.00M |
Source: https://incomestatements.info
Category: Stock Reports